Vanguard Group Inc Next Cure, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Next Cure, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 987,324 shares of NXTC stock, worth $740,493. This represents 0.0% of its overall portfolio holdings.

Number of Shares

987,324

Previous 987,324 -0.0%

Holding current value

$740,493

Previous $1.35 Million 43.79%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.13 - $2.23 $94,580 - $186,651	83,700 Added 9.26%	987,324 $2.2 Million
Q4 2023 Feb 14, 2024	BUY	$1.03 - $1.45 $202 - $285	197 Added 0.02%	903,624 $1.03 Million
Q3 2023 Nov 14, 2023	SELL	$1.29 - $1.84 $6,509 - $9,284	-5,046 Reduced 0.56%	903,427 $1.17 Million
Q4 2022 Feb 10, 2023	BUY	$1.2 - $3.07 $394 - $1,010	329 Added 0.04%	908,473 $1.28 Million
Q3 2022 Nov 14, 2022	SELL	$2.72 - $5.19 $71,293 - $136,035	-26,211 Reduced 2.81%	908,144 $2.5 Million
Q2 2022 Aug 12, 2022	BUY	$3.38 - $5.27 $826,660 - $1.29 Million	244,574 Added 35.46%	934,355 $4.39 Million
Q1 2022 May 13, 2022	SELL	$4.76 - $6.24 $294,110 - $385,557	-61,788 Reduced 8.22%	689,781 $3.35 Million
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $314,890 - $502,720	-55,244 Reduced 6.85%	751,569 $4.51 Million
Q3 2021 Nov 12, 2021	BUY	$6.74 - $8.02 $10,689 - $12,719	1,586 Added 0.2%	806,813 $5.44 Million
Q2 2021 Aug 13, 2021	BUY	$7.6 - $10.28 $6.12 Million - $8.28 Million	805,227 New	805,227 $6.47 Million

Others Institutions Holding NXTC

# of Institutions

Shares Held

14.6M

Call Options Held

Put Options Held

View Full List

About NextCure, Inc.

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $20.8M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

More about NXTC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Next Cure, Inc. Transaction History